QuantiFERON-TB Gold Plus (IGRA)

The Florida Department of Health is pursuing a single-source contract with Qiagen, LLC for the procurement of QuantiFERON-TB Gold Plus (IGRA) testing reagents and blood collection devices. Valued at $360,000, this acquisition is designated under NAICS code 325413 and is intended to support critical public health surveillance and tuberculosis outbreak detection within Palm Beach County. The procurement is justified under Chapter 60A-1.045 of the Florida Administrative Code, as Qiagen, LLC is the sole manufacturer of these FDA-approved products, which are uniquely compatible with the existing laboratory instrumentation operated by the Palm Beach County Laboratory. The scope of work focuses on maintaining the continuity of automated, quantitative measurements of Interferon-gamma to identify infected individuals and detect tuberculosis clusters. Inspection and acceptance of the deliverables will occur at the destination, the Palm Beach County Laboratory. While the solicitation was posted on July 8, 2025, with a response deadline of July 14, 2025, the procurement process is non-competitive due to the proprietary nature of the reagents. All formal submissions and protests must be delivered physically or via fax to the Department of Health in Tallahassee, as electronic filings are explicitly prohibited.